In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...
Earlier this week, British drugmaker GSK received approval in Canada for its RSV vaccine for adults aged between 50 and 59 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback